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Abstract
U.S. treatment guidelines recommend Pneumocystis jiroveci pneumonia (PCP) prophylaxis for all 
HIV-infected persons with CD4+ T-lymphocyte (CD4) counts <200 cells/μl (i.e. eligible for PCP 
prophylaxis). However, some studies suggest PCP prophylaxis may be unnecessary in virally 
suppressed patients. Using national data of HIV-infected adults receiving medical care in the 
United States during 2009–2012, we assessed the weighted percentage of eligible patients who 
were prescribed PCP prophylaxis and the independent association between PCP prophylaxis 
prescription and viral suppression. Overall, 81% of eligible patients were prescribed PCP 
prophylaxis. Virally suppressed eligible patients were less likely to be prescribed PCP prophylaxis 
(prevalence ratio, 0.84; 95% confidence interval, 0.80–0.89). Although guidelines recommend 
PCP prophylaxis for all eligible patients, some HIV care providers might not prescribe PCP 
prophylaxis to virally-suppressed patients. Additional data on the risk for PCP among virally-
suppressed patients are needed to clarify this controversy.
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Introduction
The incidence of Pneumocystis jiroveci pneumonia (PCP) among HIV-infected persons in 
the United States has declined dramatically in the era of antiretroviral therapy (ART). A 
large U.S. cohort study shows that PCP incidence has been below one case per 100 person-
years since 2000. However, PCP remains the second most frequently diagnosed AIDS-
Corresponding Author: Xia Lin, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention, CDC. 1600 Clifton Road NE, MS E-46, Atlanta, GA 30329, USA. wft4@cdc.gov. 
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.
HHS Public Access
Author manuscript
J Int Assoc Provid AIDS Care. Author manuscript; available in PMC 2017 November 01.
Published in final edited form as:













defining opportunistic illness.1 It is still a life-threatening disease even in developed 
countries with high-quality medical care. 2,3
U.S. treatment guidelines recommend PCP prophylaxis for all HIV-infected persons with a 
CD4+ T-lymphocyte (CD4) count <200 cells/μl or a history of oropharyngeal candidiasis.4 
Recent data suggest that PCP prophylaxis may be unnecessary for virally suppressed 
patients even if their CD4 counts are <200 cells/μl.5–7 In this report, we present the national 
percentage of HIV-infected persons with a CD4 count <200 cells/μl who were prescribed 
PCP prophylaxis, and evaluate socio-demographic and clinical characteristics that may be 
associated with PCP prophylaxis prescription, in particular, durable viral suppression.
Methods
The Medical Monitoring Project (MMP) is a supplemental surveillance system designed to 
produce nationally representative estimates of behavioral and clinical characteristics of HIV-
infected adults receiving medical care in the United States and Puerto Rico.8 MMP utilizes a 
three-stage, complex sampling design in which US states and territories are sampled, 
followed by facilities providing outpatient HIV medical care in those jurisdictions, then 
HIV-infected adults (aged 18 years and older) receiving care in those facilities. Data were 
collected by interviews and medical record abstractions. The surveillance period included 
the 12 months prior to interview. We combined data from the 2009 through 2012 cycles for 
this analysis. All sampled states and territories participated and the facility response rates 
were 76% – 85% across all years. Approximately 50% (ranging from 47% to 53% across 
years) of eligible persons sampled from these facilities completed an interview and had their 
medical records abstracted. Data were weighted to account for unequal selection 
probabilities, and both facility and patient nonresponse.
MMP is a public health surveillance activity and not subject to federal institutional review 
board (IRB) review.9 However, some jurisdictions obtained local IRB approvals. All 
participants provided informed consent to participate.
We analyzed data on 2143 patients who had at least one CD4 count <200 cells/μl during the 
first 6 months of the surveillance period to allow adequate opportunity for providers to 
prescribe PCP prophylaxis. We excluded 154 patients who were diagnosed with PCP during 
the surveillance period to avoid potential misclassification of PCP treatment as prophylaxis.
CD4 count, HIV plasma viral load, and prescription information were abstracted from 
medical records. Durable viral suppression was defined as all viral load results <200 
copies/ml during the surveillance period. Provider prescription of PCP prophylaxis was 
ascertained via medical record documentation of PCP “prophylaxis”, or documentation that 
the patient was either prescribed or continued on medical regimens typically provided for 
prophylaxis. Brief antibiotic prescriptions for two weeks or less were likely treatment of an 
acute infection and therefore were not considered as prophylaxis. Medications included 
atovaquone, aapsone, leucovorin, pentamidine, pyrimethamine, and trimethoprim-
sulfamethoxazole. Medical record abstractors received training on how to identify and 
abstract PCP prophylaxis for quality assurance. We assessed the weighted percentage of 
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HIV-infected patients with a CD4 count <200 cells/μl who were prescribed PCP 
prophylaxis. We also assessed the association between selected characteristics and PCP 
prophylaxis prescription using bivariate analysis (Rao-Scott chi-square test). Durable viral 
suppression was of particular interest so we employed a multivariable logistic regression 
model to elucidate its independent association with PCP prophylaxis prescription. In this 
multivariable modeling process, we considered socio-demographic and clinical factors that 
were associated with both durable viral suppression and PCP prophylaxis prescription, 
including race, education, poverty, homelessness, length of HIV diagnosis, and 
hospitalization, as potential confounders. Only potential confounders that changed the 
association by at least 10%, as measured by the prevalence ratio, were retained in the final 
model.
All analyses accounted for the complex sample design by using the survey procedures in 
SAS 9.3 and SUDAAN 10.0.1.
Results
The socio-demographic and clinical characteristics of patients who had at least one CD4 
count <200 cells/μl are shown in table 1. Among them, 64% had durable viral suppression, 
and 81% were prescribed PCP prophylaxis. Patients with a PCP prophylaxis prescription 
were not significantly different from patients without a prescription with regards to gender, 
age, education, homelessness, illicit drug use (excluding marijuana), or hospitalization 
(p>0.05). Patients of white or Hispanic race/ethnicity, those above poverty level, or 
diagnosed with HIV for 5 years or more were less likely to be prescribed PCP prophylaxis 
(p<0.05).
During the logistic regression model selection process, the change in the association 
between durable viral suppression and PCP prophylaxis prescription by potential 
confounders ranged from 0% to 2% so no confounders were included in the final model. 
Therefore, we used the unadjusted prevalence ratio to measure the independent association 
between durable viral suppression and PCP prophylaxis prescription. Virally suppressed 
patients were 16% less likely to be prescribed PCP prophylaxis (prevalence ratio= 0.84; 95% 
confidence interval, 0.80–0.89) compared with patients who were not virally suppressed.
Of note, among patients with a CD4 count <200 cells/μl who were not virally suppressed, 
14% were not prescribed PCP prophylaxis (Table 1). In addition, 13% of the patients with a 
CD4 count <100 cells/μl were not prescribed PCP prophylaxis, regardless of viral loads 
(Table 1).
Discussion
Using nationally representative data of HIV-infected adults receiving medical care in the 
United States during 2009–2012, we estimated that 81% of patients who had at least one 
CD4 count <200 cells/μl were prescribed PCP prophylaxis. Our estimate indicates improved 
adherence to guidelines compared with the 2003 estimate of 76% produced using the 
Centers for Disease Control and Prevention’s Adult/Adolescent Spectrum of HIV Disease, 
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which assessed trends in receipt of PCP prophylaxis among HIV-infected persons in the 
United States during 1994–2003.10
We also found that among patients indicated for PCP prophylaxis, virally suppressed 
patients (viral loads <200 copies/ml) were less likely to be prescribed PCP prophylaxis 
compared with patients with HIV viral loads ≥ 200 copies/ml. Several recent studies have 
found a low incidence of PCP in HIV-infected persons with CD4 count < 200 cells/μl if they 
are on ART and virally suppressed, and this may explain why providers in our analysis were 
less likely to prescribe PCP prophylaxis to virally suppressed patients. A large European 
cohort study and a case series found that PCP prophylaxis may be safely discontinued for 
patients who had plasma viral loads <400 to 500 copies/ml and had CD4 counts 100–200 
cells/μl, but not for patients who had CD4 counts <100 cells/μl, regardless of viral 
suppression status.6,11 One clinical trial and two case-series revealed that PCP prophylaxis 
may be unnecessary for virally suppressed patients, regardless of CD4 count; however, they 
did not compare PCP incidence among virally suppressed patients with CD4 counts <100 
cells/μl and patients with CD4 counts 100–200 cells/μl.7,12, 13
Patients with advanced immunosuppression are more likely to be diagnosed with PCP.14 In 
our analysis, we found that >10% of HIV-infected patients with CD4 counts < 100 cells/μl 
were not prescribed PCP prophylaxis. Given the lack of evidence to support discontinuation 
of PCP prophylaxis for patients with CD4 counts <100 cells/μl, prophylaxis is warranted in 
these individuals.
The major strengths of our analysis are that we generated national estimates on percentages 
of HIV-infected patients who were prescribed PCP prophylaxis by characteristics. There are 
at least two limitations to this analysis. First, while current treatment guidelines recommend 
PCP prophylaxis for all patients who have a CD4 count <200 cells/μl, a history of 
oropharyngeal candidiasis, CD4 cell percentage of <14%, or a history of an AIDS-defining 
illness, we used CD4 count <200 cells/μl as our sole criterion for inclusion. Per treatment 
guidelines, CD4 count <200 cells/μl has the strongest evidence to support use of PCP 
prophylaxis compared to the other criteria and should cover the majority of patients eligible 
for PCP prophylaxis. Second, given the cross-sectional nature of the analysis, we may have 
failed to capture PCP prophylaxis prescriptions provided after the end of the data collection 
period. To minimize this concern, we limited the analysis to participants who had at least 
one CD4 count <200 cells/μl during the first 6 months of the surveillance period to allow 
providers opportunities to prescribe prophylaxis if warranted.
In summary, 81% of HIV-infected persons with at least one CD4 count < 200 cells/μl were 
prescribed PCP prophylaxis. Compared with patients who had detectable HIV viral loads 
(≥200 copies/ml), virally suppressed patients were less likely to be prescribed PCP 
prophylaxis. While recent data suggest that PCP prophylaxis may be safely discontinued in 
virally suppressed patients with CD4 counts between 100–200 cells/μl, the Panel on 
Opportunistic Infections in HIV-Infected Adults and Adolescents has determined that 
evidence is insufficient to change current recommendations.4 Additional data on patient 
characteristics associated with PCP incidence in the ART era are needed to determine which 
individuals are at the highest risk for PCP and would benefit most from PCP prophylaxis.
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Table 1
Socio-demographic and clinical characteristics of HIV-infected persons with a CD4 cell count <200 cells/μl 
and receiving medical care in the United States, Medical Monitoring Project, 2009–2012.
Characteristic Total (n=2143)Weighted % (95% CI)
Prescribed PCP 
prophylaxis (n=1753)
Weighted % (95% CI)
Not prescribed PCP 
prophylaxis (n=390)
Weighted % (95% CI)
P for Rao-Scott 
chi-square test
Total (n=2143) 81 (79–84) 19 (16–22)
All viral loads < 200 copies/mla,e
 Yes 64 (61–66) 73 (69–77) 27 (23–31) <0.001
 No 36 (34–39) 86 (84–89) 14 (11–16)
Gender
 Male 73 (71–76) 81 (78–84) 19 (16–22) 0.925
 Female 27 (24–29) 82 (77–86) 18 (14–23)
Age (years)
 18–29 6 (5–8) 88 (82–94) 12 (6–18) 0.128
 30–39 18 (16–20) 83 (78–89) 17 (11–22)
 40–49 38 (36–41) 82 (78–85) 18 (15–22)
 ≥50 38 (35–40) 79 (75–83) 21 (17–25)
Race and ethnicity
 White, non-Hispanic 27 (21–32) 77 (72–82) 23 (18–28) 0.001
 Black, non-Hispanic 49 (42–57) 85 (82–88) 15 (12–18)
 Hispanic or Latino 19 (14–24) 78 (73–83) 22 (17–27)
 Other 5 (4–7) 82 (74–91) 18 (9–26)
Education
 <High school 27 (25–30) 84 (80–87) 16 (13–20) 0.054
 High school 30 (27–32) 83 (79–87) 17 (13–21)
 >High school 43 (40–46) 79 (76–82) 21 (18–24)
Poverty levela,b,e
 Above poverty level 44 (41–48) 79 (76–83) 21 (17–24) 0.022
 Below or at poverty level 56 (52–59) 83 (80–86) 17 (14–20)
Experienced homelessnessa
 Yes 12 (11–14) 86 (81–91) 14 (9–19) 0.073
 No 88 (86–89) 81 (78–84) 19 (16–22)
Any illicit drug usea,c
 Yes 15 (13–17) 84 (80–89) 16 (11–20) 0.167
 No 85 (83–87) 81 (78–84) 19 (16–22)
Length of time HIV diagnosede
 <5 years 26 (24–29) 86 (82–89) 14 (11–18) 0.015
 5–9 years 18 (16–19) 81 (77–86) 19 (14–23)
 ≥10 years 56 (53–59) 80 (76–83) 20 (17–24)
Hospitalizeda,d
 Yes 22 (20–25) 84 (80–88) 16 (12–20) 0.071
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Characteristic Total (n=2143)Weighted % (95% CI)
Prescribed PCP 
prophylaxis (n=1753)
Weighted % (95% CI)
Not prescribed PCP 
prophylaxis (n=390)
Weighted % (95% CI)
P for Rao-Scott 
chi-square test
 No 78 (75–80) 81 (78–83) 19 (17–22)
Lowest CD4 count (cells/μl)a
 0–99 48 (46–50) 87 (82–91) 13 (9–18) 0.001
 100–199 52 (50–54) 77 (74–80) 23 (20–26)
Abbreviations: CI, confidence interval; DHHS, Department of Health and Human Services; PCP, Pneumocystis jiroveci pneumonia.
a
The surveillance period, 12 months before interview..
b
This measure uses the DHHS Poverty Guidelines to determine whether respondent’s household is above or below the poverty level.
c
Any illicit drug use excluding marijuana.
d
Hospitalized at least once in the 12 months prior to interview; based on both interview and medical records.
e
Missing n: all viral loads < 200 copies/ml, 39; poverty, 69; length of HIV diagnosis, 2.
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